Pharmacological Treatment of Tourette Disorder

Year 2013, Volume: 5 Issue: 2, 246 - 259, 01.06.2013

Hande Ayraler Taner Esra Güney Yasemen Taner

https://doi.org/10.5455/cap.20130516

Abstract

Tourette disorder is a chronic neuropsychiatric disorder characterized by vocal and motor tics. The course of the disorder shows waxing and vaning pattern and symptoms adversely affect patients' quality of life. Patients use psychopharmacologic agents for long periods to control their symptoms during which they also struggle with drug related side effects. Clinicians face serious difficulties in controlling symptoms with psychopharmacological agents. Primarily alpha 2 receptor agonists and antipsychotic drugs have been used in the treatment of Tourette disorder. Risperidone and aripiprazole are the most commonly used new generation antipsychotics in the treatment. In addition there are contradictory findings regarding the use of dopamine agonists, tetrabenazine, topiramate, levatirasetame, and delta-9-tetrahydrocannabinol in these patients.

Keywords

Tourette Disorder, tics, antipsychotic drugs

Tourette Bozukluğunda İlaç Tedavisi

Abstract

Tourette bozukluğu motor ve vokal tiklerle karakterize kronik bir nöropsikiyatrik bozukluktur. Hastalığın seyrinde belirtilerde zaman zaman düzelmeler ve alevlenmeler görülebilmekte ve belirtiler hastaların yaşam kalitesini azaltmaktadır. Hastalar belirtilerinin tedavisi için uzun süre ilaç tedavisi almak zorunda kalmakta ve bunun yanı sıra pek çok ilaç yan etkisi ile karşılaşmaktadırlar. Tourette bozukluğu belirtilerinin farmakoterapi ile kontrolü kimi olgularda klinisyenleri ciddi bir şekilde zorlamaktadır. Tourette bozukluğu tedavisinde en sık alfa 2 reseptör agonistleri ve antipsikotik ilaçlar kullanılmaktadır. Tourette bozukluğu tedavisinde en sık kullanılan yeni nesil antipsikotikler risperidon ve aripiprazoldür. Bunun yanı sıra çelişkili sonuçları olan dopamin agonistleri, tetrabenazin, topiramat, levatirasetam ve delta-9-tetrahidrokannabinol ile yapılan yeni çalışmalar da mevcuttur.

Keywords

Tourette Bozukluğu, tikler, antipsikotik ilaçlar.

References

• Bloch MH, Leckman JF. Tic disorders. In Lewis’s Child and Adolescent Psychiatry: A Comprensive Textbook, 4th ed. (Eds A Martin, FR Volkmar):569-583. Philadelphia, Lippincott Williams Wilkins, 2007.
• McNaught K St.P, Mink JW. Advances in understanding and treatment of Tourette syndrome. Nat Rev Neurol 2001; 7:667-676.
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington DC, American Psychiatric Association, 2000.
• Carter AS, Pauls DL, Leckman JF, Cohen DJ. A prospective longitudinal study of Gilles de la Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1994; 33:377
• Jankovic J. Tourette's syndrome. N Engl J Med 2001; 345:1184-1192.
• Robertson MM. The Gilles de la Tourette Syndrome: the current status. Arch Dis Child Educ Pract Ed 2012; 97:166-175.
• Cheung MY,Shahed C, Jankovic J. Malignant Tourette syndrome. Mov Disord 2007; 22:1743-1750.
• Hyde TM, Aaronson BA, Randolph C, Rickler KC, Weinberger DR. Relationship of birth weight to the phenotypic expression of Gilles de la Tourette's syndrome in monozygotic twins. Neurology 1992; 42:652-658.
• Price RA, Kidd KK, Cohen DJ, Pauls DL, Leckman JF. A twin study of Tourette syndrome. Arch Gen Psychiatry 1985; 42:815-820.
• Braun AR, Stoetter B, Randolph C, Hsiao JK, Vladar K, Gernert J et al. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I: regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology 1993; 9:277-291.
• Braun AR, Randolph C, Stoetter B, Mohr E, Cox C, Vladar K et al.The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. II: relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness, Neuropsychopharmacology 1995; 13:151-168.
• Albin RL, Koeppe RA, Bohnen NI, Nichols TE,Meyer P,Wernette K et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome Neurology 2003; 61:310-315.
• Semerci B. Tik Bozuklukları. In Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları, 1.baskı (Eds A Aysev, Y Taner):603-613. İstanbul, Golden Print, 2007.
• Hallett JJ, Harling-Berg CJ, Knopf PM, Stopa EG, Kiessling LS. Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction. J Neuroimmunol 2000; 111:195-202.
• Tourette Syndrome Study Group.treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58:527-536.
• Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment, Eur Child Adolesc Psychiatry 2011; 20:173-196.
• King A, Harris P, Fritzell J, Kurlan R. Syncope in children with Tourette’s syndrome treated with guanfacine. Mov Disord 2006;21:419-420.
• Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E et al.A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158:1067-1074. Eddy CM, Rickards HE, Cavanna AE. Treatment strategies for tics in Tourette syndrome Ther Adv Neurol Disord 2011; 4:25-45.
• Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder. Am J Psychiatry 1997; 154:1057-1062.
• Pringsheim T, Marras C. Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev 2009; 2: CD006996.
• Singer HS, Gammon K, Quaskey S. Haloperidole, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985-86; 12:71-74. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry 2007; 16:104-120.
• Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo controlled trial of risperidone in Tourette syndrome. Neurology 2003; 60:1130-1135.
• Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebocontrolled trial. J Clin Psychopharmacol. 2002; 22:31-39.
• Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 2002; 41:330-336.
• Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39:292-299.
• Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry 2007; 68:1088-1093.
• Budman C, Coffey BJ, Shechter R, Schrock M, Wieland N, Spirgel A et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008; 18:509-515.
• Murphy TK, Mutch PJ, Reid JM, Edge PJ, Storch EA, Bengtson M et al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 2009; 19:441-447.
• Bozkurt H, Ayaydin H, Abali O. Letter to the Editor. Klinik Psikofarmakoloji Bülteni 2009; 19:447-448.
• Gulisano M, Calı` PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 2011; 32:1213-1217.
• McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette Syndrome. J Child Adolesc Psychopharmacol 2008; 18:501-508.
• Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome: a pilot study, J Child Adolesc Psychopharmacol 2004; 14:255-266.
• Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD. An open-label study of the treatment efficacy of olanzapine for Tourette’s disorder, J Clin Psychiatry 2001; 62:290-294.
• Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol 2003; 13:295-299.
• Copur M, Arpaci B, Demir T, Narin H. Clinical effectiveness of quetiapine in children and adolescents with Tourette's syndrome: a retrospective case-note survey, Clin Drug Investig. 2007;27:123-130.
• Robertson MM, Schnieden V, Lees AJ. Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990; 13:229-235.
• Ho CS,Chen HJ,Chiu NC,Shen EY, Lue HC. Short-term sulpiride treatment of children and adolescents with tourette syndrome or chronic tic disorder. J Formos Med Assoc 2009; 108:788–793.
• Kozian R, Friederich M. Gilles-de-la-Tourette Syndrome as a tardive dyskinesia. Psychiatr Prax 2007; 34:253-254.
• Müller-Vahl KR. The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome. Nervenarzt 2007; 78:264,266-268,270-271.
• Fountoulakis KN, Iacovides A, St Kaprinis G. Successful treatment of Tourette's disorder with amisulpride, Ann Pharmacother 2004; 38:901.
• Black KJ, Mink JW. Response to levodopa challenge in Tourette syndrome. Mov Disord 2000; 15:1194-1198.
• Anca MH, Giladi N, Korczyn AD. Ropinirole in Gilles de la Tourette syndrome. Neurology 2004; 62:1626-1627.
• Cianchetti C,Fratta A, Pisano T ,Minafra L, Pergolide improvement in neurolepticresistant Tourette cases: various mechanisms causing tics Neurol Sci 2005; 26:1371
• Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009; 8:844-856.
• Kuo SH, Jimenez-Shahed J, Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol 2010; 33:32-34.
• Oulis P, Karapoulios E, Masdrakis VG, Kouzoupis AV, Karakatsanis NA, Papagregorgiu C et al. Levetiracetam in the treatment of antipsychotics-resistant Tourette syndrome. World J Biol Psychiatry 2008; 9:76-77.
• Awaad Y, Michon AM, Miratik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Dis 2005; 20:714-718.
• Awaad YM, Michon AM, Minarik S. Long-term follow-up use of levetiracetam to treat tics in children. Ann Neurol 2005; 58:112.
• Singer HS, Wendlandt J, Krieger M, Giuliano J. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001; 56:599-604.
• Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM et al. Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther 1997; 74:21-25. McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry 1992; 31:832-840.
• Howson AL, Batth S, Ilivitsky V, Boisjoli A, Jaworski M, Mahoney C et al. Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome. Eur Psychiatry 2004 ;19:102-112.
• Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebocontrolled study. J Clin Psychiatry 2001; 62:707-714.
• Dursun SM, Reveley MA, Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study, Psychol Med 1997; 27:483-487.
• Leckman JF, Scahill L. Possible exacerbation of tics by androgenic steroids. N Engl J Med 1990; 322:1674.
• Muroni A, Paba S, Puligheddu M, Marrosu F, Bortolato M, A preliminary study of finasteride in Tourette syndrome, Mov Disord 2011; 26:2146-2147.
• Bortolato M, Muroni A, Marrosu F. Treatment of Tourette’s syndrome with finasteride. Am J Psychiatry 2007;164:1914-1915.
• Muller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T et al..Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol [THC]: a randomized crossover trial. Pharmacopsychiatry 2002; 35:57-61.
• Muller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U.Treatment of Tourette syndrome with delta- 9-tetrahydrocannabinol [delta 9THC]: no influence on neuropsychological performance. Neuropsychopharmacology 2003; 28:384-388.
• Ak M, Uzun Ö, Özmenler KN, Cöngeloğlu E, Bozkurt A, Özşahin A. Tourette sendromlu olgularda nöropsikiyatrik bulgular. Gülhane Tıp Dergisi 2011; 53:89-93. Hande Ayraler Taner, Dr., Gazi Üniv.Tıp Fakültesi Çocuk ve Ergen Psikiyatrisi ABD,Ankara; Esra Güney, Uzm. Dr., Ankara Çocuk Sağlığı ve Hast. Hematoloji-Onkoloji Eğitim Araştırma Hastanesi Çocuk Ruh Sağlığı ve Hastalıkları Bölümü, Ankara; Yasemen Taner, Doç. Dr., Gazi Üniv.Tıp Fakültesi Çocuk ve Ergen Psikiyatrisi ABD,Ankara. Yazışma Adresi/Correspondence: Hande Ayraler Taner, Gazi Üniv.Tıp Fakültesi Çocuk ve Ergen Psikiyatrisi ABD,Ankara, Turkey. E-mail: [e-mail] Yazarlar bu makale ile ilgili herhangi bir çıkar çatışması bildirmemişlerdir. The authors reported no conflict of interest related to this article. Çevrimiçi adresi / Available online at: www.cappsy.org/archives/vol5/no2/ Çevrimiçi yayım / Published online 27 Şubat/February 27, 2013; doi:10.5455/cap.20130516